Fulcrum Therapeutics (FULC) Change in Acquisitions & Divestments (2020 - 2026)

Fulcrum Therapeutics (FULC) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $37.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments fell 58.34% year-over-year to $37.7 million; the TTM figure through Jun 2026 stood at $126.0 million (down 41.76% YoY), while the FY2025 annual figure was $211.3 million, changed 0.07% from the prior year.
• Change in Acquisitions & Divestments rose to $37.7 million in Q2 2026 per FULC's latest filing, from $27.1 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $94.0 million in Q1 2024 and bottomed at $23.9 million in Q4 2024.
• Historically, Change in Acquisitions & Divestments has averaged $45.1 million across 5 years, with a median of $42.7 million in 2022.
• Annual changes were most pronounced in 2024 — Change in Acquisitions & Divestments surged 187.08% — and 2026, when it plunged 58.34%.
• Fulcrum Therapeutics' Change in Acquisitions & Divestments stood at $47.0 million in 2022, then fell by 7.52% to $43.5 million in 2023, then sank by 45.06% to $23.9 million in 2024, then increased by 5.64% to $25.2 million in 2025, then surged by 49.14% to $37.7 million in 2026.
• Business Quant data shows FULC's Change in Acquisitions & Divestments at $37.7 million in Q2 2026, $27.1 million in Q1 2026, and $25.2 million in Q4 2025.